Alkermes, Inc. (ALKS) Third-Quarter Review
February 05, 2010 4:12 PM
Analysts at Leerink Swann have released a report reviewing the third-quarter at Alkermes, Inc. (NASDAQ: ALKS). The company reported results for the third-quarter yesterday.
Alkermes, Inc. reported revenue of $44 million, which was above analysts’ estimate of $38 million. The company reported a loss of $0.07 per share for the quarter. Analysts had estimated a loss of $0.19 per share. The company reported sales of $5.5 million for Vivitrol in the third-quarter, a 17% quarter-over-quarter increase, but short of the $10 million mark needed to break even.
Analysts have an Outperform rating for Alkermes, Inc. According to analysts, the company provides an attractive risk/reward profile. Analysts expect the company’s value to reach around $12-$13 per share in 12 months.
According to analysts, the key risks to valuation include poor results from any ongoing clinical trials, significant loss of Risperdal Consta market share, unfavorable or delayed regulatory decisions, and positive clinical trial results from competitors to the company’s products.
